Home/Pipeline/GM-2505

GM-2505

Undisclosed Inflammatory Dermatosis

Phase 1Active

Key Facts

Indication
Undisclosed Inflammatory Dermatosis
Phase
Phase 1
Status
Active
Company

About Galderma

Galderma's mission is to advance dermatology for every skin story, establishing itself as the world's most trusted leader in skin health. The company has achieved this through a resilient, tri-segment business model, a robust R&D engine, and a successful 2024 IPO that marked Europe's largest of the year. Its strategy centers on driving growth through innovation in its core aesthetics and prescription franchises, expanding its consumer care reach, and leveraging its global commercial infrastructure to maintain a competitive edge in the dynamic dermatology market.

View full company profile